Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | BRAF |
Variant | V600M |
Impact List | missense |
Protein Effect | gain of function - predicted |
Gene Variant Descriptions | BRAF V600M (previously reported as V599) lies within the activation segment of the kinase domain of the Braf protein (PMID: 15035987). V600M results in intermediate Braf kinase activity in cell culture (PMID: 28783719), and in one of two cell lines increased cell proliferation and cell viability compared to wild-type Braf (PMID: 29533785), and therefore, is predicted to lead to a gain of Braf protein function. |
Associated Drug Resistance | |
Category Variants Paths |
BRAF mutant BRAF act mut BRAF V600M BRAF mutant BRAF V600X BRAF V600M |
Transcript | NM_004333.6 |
gDNA | chr7:g.140753337C>T |
cDNA | c.1798G>A |
Protein | p.V600M |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_004333.6 | chr7:g.140753337C>T | c.1798G>A | p.V600M | RefSeq | GRCh38/hg38 |
NM_001354609.2 | chr7:g.140753337C>T | c.1798G>A | p.V600M | RefSeq | GRCh38/hg38 |
NM_001354609.1 | chr7:g.140753337C>T | c.1798G>A | p.V600M | RefSeq | GRCh38/hg38 |
NM_004333.5 | chr7:g.140753337C>T | c.1798G>A | p.V600M | RefSeq | GRCh38/hg38 |
XM_005250045 | chr7:g.140753337C>T | c.1798G>A | p.V600M | RefSeq | GRCh38/hg38 |
NM_004333 | chr7:g.140753337C>T | c.1798G>A | p.V600M | RefSeq | GRCh38/hg38 |
NM_001378474.1 | chr7:g.140753337C>T | c.1798G>A | p.V600M | RefSeq | GRCh38/hg38 |
NM_001378468.1 | chr7:g.140753337C>T | c.1798G>A | p.V600M | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03839342 | Phase II | Binimetinib + Encorafenib | Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations (BEAVER) | Active, not recruiting | CAN | 0 |
NCT04061980 | Phase II | Binimetinib + Encorafenib Binimetinib + Encorafenib + Nivolumab | Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer | Active, not recruiting | USA | 0 |